Abstract 113P
Background
Our real-world data show high response rates with the COIB regimen for mCRC (Liu, Ou et al. 2022). But the appropriate dosage needs to be carefully explored. Therefore, we designed this prospective phase I/II study to determine the efficacy and tolerability of this combination regimen in the first-line treatment of mCRC.
Methods
This study consists of dose escalation (DES) and dose expansion (DEX). The primary objective in DES phase was to evaluate safety and tolerability of I combined with COB, followed by a DEX phase to verify the safety and tolerability profile of the combination therapy. Primary endpoints included recommended phase ll dose (RP2D) and efficacy of the combination. Other end points included exploratory biomarkers of drug activity. I was administered once a day (QD) at two dose levels (150mg/㎡ or 165mg/㎡) in combination with C (1g/㎡ bid, day 1-7)+ O (85mg/㎡, day 1)+B (5mg/kg, day 1), every 14 days (Q2W).
Results
As of August 13, 2023, 97 pts (median age: 58 years; 30% female; 77% left-sided intestine; 43 KRAS mutation, 6 NRAS mutation, 4 BRAF mutation, 31 wild type, 13 unknown) were treated (6 in DES, 91 in DEX). None of the 3 pts in irinotecan dose level 1 or 3 pts in irinotecan dose level 2 of DES had dose limiting toxicities (DLTs), and irinotecan (165mg/㎡, day1) was the RP2D. Treatment-related adverse events (TRAEs) of any grade occurred in 87 (89.7%) pts. TRAEs of grade ≥ 3 were mainly myelosuppression (20 pts, 20.6%) and diarrhea (10 pts, 10.3%). There were no fatal TRAEs. Of 90 pts evaluable for response, Objective response rate (ORR) was 73.3% (95% CI: 64.1%, 82.4%), Disease control rate (DCR) was 98.8% (95% CI: 96.7%, 100.0%).22 patients were successfully transformed and underwent radical resection, No evidence of disease (NED) rate was 22.7% (95% CI: 14.4%, 31.0%). With median follow-up of 17.0 months, 46 pts had progressive disease, median progression free survival (PFS) was 13.0 months(95%CI: 10.8, 19.3), overall survival (OS) are not yet mature. Detection biomarkers of drug activity is in progress.
Conclusions
The RP2D of irinotecan in COIB regimen is 165 mg/m2. The efficacy of the regimen is promising with well tolerance.
Clinical trial identification
NCT04380103.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Development Project of Medical Oncology Key Foundation of Cancer Hospital Chinese Academy of Medical Sciences (CICAMS-MODP2022002).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
228P - Real-world data on dose adjustment of cabozantinib in advanced renal cell carcinoma
Presenter: Hemavathi Baskarane
Session: Poster Display
Resources:
Abstract
229P - The application of diffusion kurtosis imaging in predicting muscle invasion of bladder cancer: A comparison with conventional DWI
Presenter: Shuai Jiang
Session: Poster Display
Resources:
Abstract
230P - Oncological outcomes between partial cystectomy and radical cystectomy in solitary muscle invasive bladder cancer with downgraded T stage
Presenter: Ming Wei Hsu
Session: Poster Display
Resources:
Abstract
231P - BMI-predicted progression-free survival after pembrolizumab therapy for urothelial cancer: Asian version of BMI classification is suitable for Asian patients
Presenter: mirii harada
Session: Poster Display
Resources:
Abstract
232P - The immunosuppressive features of the 20S Proteasome β-subunit gene family in von Hippel-Lindau (VHL)-mutated clear cell renal cell carcinoma (ccRCC): A TCGA-based bioinformatics study
Presenter: Saja Alzghoul
Session: Poster Display
Resources:
Abstract
233P - The crosstalk between PBRM1 loss and tumor immune microenvironment (TIME) of clear cell renal cell carcinoma (ccRCC): A possible interconnection to immunotherapy response
Presenter: Ahmed Al Sharie
Session: Poster Display
Resources:
Abstract
235P - Do FGFR2 and 3 proteins have a role in the prognosis of urothelial bladder carcinoma?
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
236P - The effects of chemotherapy on body composition in patients with advanced urothelial carcinoma
Presenter: KOSUKE KITAMURA
Session: Poster Display
Resources:
Abstract
237P - Real-world analysis of adjuvant nivolumab in resected urothelial cancer: A single institute study in Taiwanese patients
Presenter: Mu-Hsin Chang
Session: Poster Display
Resources:
Abstract
238P - Enfortumab-vedotin for metastatic urothelial carcinoma refractory to platinum-based chemotherapy and immune checkpoint inhibitors: A single institution experience
Presenter: Yuki Endo
Session: Poster Display
Resources:
Abstract